HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Hiroo Takayama Gabriel S. Aldea Edward D. Verrier Christopher T. Salerno Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Takayama, H. Articles by Salerno, C. T. Search for Related Content PubMed PubMed Citation Articles by Takayama, H. Articles by Salerno, C. T. Related Collections Transplantation - heart

Eur J Cardiothorac Surg 2007;31:457-461. doi:10.1016/j.ejcts.2006.12.014
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Is pre-transplant vascular disease a risk factor for mortality and morbidity after heart transplantation?

^a Department of Cardiothoracic Surgery, University of Tokyo, Tokyo, Japan
^b Division of Cardiothoracic Surgery, University of Washington, Seattle, WA 98115, United States
^c Department of Surgery, University of Washington, Seattle, WA 98115, United States
^d Division of Cardiology, University of Washington, Seattle, WA 98115, United States

Received 16 August 2006; received in revised form 5 December 2006; accepted 7 December 2006.

^_* Corresponding author. Address: Division of Cardiothoracic Surgery, University of Washington, 1959 NE Pacific, Seattle, WA 98195, United States. (Email: csalerno{at}u.washingon.edu).

Background: Severe vascular disease is a relative contraindication to heart transplantation (HTx). We addressed the effect of vascular disease on HTx outcomes. Methods: This is a nonconcurrent cohort study of 402 patients who received HTx at our institution between 1985 and 2004. Pre-transplant vascular evaluation included carotid, lower extremity, and renal artery duplex studies, and CT angiogram when indicated. Patients with severe and nontreatable vascular disease were excluded. Patients were divided into Group 1: those with pre-transplant vasculopathy, and Group 2: those without pre-transplant vasculopathy. Group 1 had 24 patients with 25 vascular lesions: 1 aortic dissection, 2 abdominal aortic aneurysm (AAA)'s, 5 carotid artery stenoses, 1 renal artery stenosis, and 16 peripheral vascular lesions. Interventions were performed to 15 lesions prior to HTx and to 2 lesions after HTx. Results: Median follow-up was 5.5 years. Group 1 had higher incidence of ischemic cardiomyopathy (p < 0.001), hypertension (p = 0.028), chronic obstructive pulmonary disease (COPD) (p = 0.004), and smoking history (p < 0.001). There were no differences in sex, hyperlipidemia, diabetes, stroke, or renal dysfunction. Multivariate analysis revealed odds of post-transplant death in Group 1 was 1.4 (95% CI: 0.48–4.1, p = 0.54) times greater than that in Group 2. Cox proportional hazards model for survival showed a 50% increase in the hazard of death in patients with pre-transplant vasculopathy, but without statistical significance. Group 1 had higher incidence of post-transplant stroke (p = 0.001) but no difference in allograft coronary atherosclerosis. Conclusions: Pre-transplant vascular disease seems to have negative effect on outcomes after HTx. Larger scale study is needed for further evaluation.

Key Words: Heart transplantation • Vascular disease • Mortality • CVA • Allograft coronary artery disease